ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO940

Low Prevalence of Class 1 Indications for Coronary Revascularization in Patients Undergoing Prekidney Transplant Screening for Coronary Disease

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Israni, Avantika, New York University, New York, New York, United States
  • Sandorffy, Bronya L., New York University, New York, New York, United States
  • Liu, Celina S., New York University, New York, New York, United States
  • Fraticelli Ortiz, Daniela Isabelle, New York University, New York, New York, United States
  • Gross, Haley, New York University, New York, New York, United States
  • Nicholson, Joey, New York University, New York, New York, United States
  • Cazes, Miri, New York University, New York, New York, United States
  • Soomro, Qandeel H., New York University, New York, New York, United States
  • Charytan, David M., New York University, New York, New York, United States
Background

CVD is the most common cause of morbidity and mortality in kidney transplant recipients. Screening for coronary disease is to reduce the risk of perioperative cardiovascular complications, long term cardiovascular morbidity and mortality is frequently required but coronary intervention has not been shown to be beneficial except in complex coronary disease. The likelihood of finding significant coronary artery disease and benefit of routine pre-transplant screening is uncertain.

Methods

We performed a systematic review and meta-analysis to quantify the frequency of detecting significant coronary lesions for which--there are AHA Class 1 indications for revascularization: a) >50% left main stenosis; or b) multi-vessel disease with EF < 35%. Medline & Embase were searched to identify manuscripts reporting the results of pre-transplant screening published between 1998 and 2024.
Screening and data collection was performed by 4 independent authors with disagreements resolved by consensus. Quality assessment was performed using the Joanna Briggs Institute scale.
This review was registered with PROSPERO.

Results

We identified 1281 studies, 148 required full text review out of which 50 met eligibility criteria. We extracted data from 50 studies, 17 studies did not report ejection fraction. The mean prevalence of a class 1 indication across these studies was 5.35 %. Analysis of the number of patients with left main disease, triple vessel disease (without an EF < 35%) will be updated.

Conclusion

Identification of class I indications for revascularization during pre-transplant coronary screening is rare and routine screening may not be warranted.